Identification of predictive biomarkers for nivolumab efficacy in non-small cell lung cancer through integrated serum lipidomics and proteomics analysis

ABSTRACT: Proteomic data from pre-treatment serum samples obtained from 42 patients with non-small cell lung cancer treated with nivolumab (22 responders and 20 non-responders). The dataset consists of two proteomic layers: depleted serum proteome and serum-derived extracellular vesicle (EV) proteome. Serum proteomic data were acquired by data-independent acquisition (DIA) using an Orbitrap Eclipse Tribrid mass spectrometer and analyzed using DIA-NN version 1.8.1 in library-free mode. EV proteomic data were acquired by DIA using an Orbitrap Astral mass spectrometer and analyzed using DIA-NN version 1.9.1 in library-free mode. These data were used to investigate proteomic signatures associated with response to nivolumab in patients with non-small cell lung cancer.

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Hiroaki Hase 

PROVIDER: PXD084678 | JPOST Repository | Thu Sep 24 00:00:00 GMT+01:00 2026

REPOSITORIES: jPOST